Home LiteratureArticle Details
PMID: 18677108 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells.

Cell cycle (Georgetown, Tex.) ·Vol. 7 ·No. 15 ·2008-08-00 ·Pages 2392-400

Mannava S, Grachtchouk V, Wheeler LJ, Im M, Zhuang D, Slavina EG, Mathews CK, Shewach DS, Nikiforov MA

Abstract

To identify C-MYC targets rate-limiting for proliferation of malignant melanoma, we stably inhibited C-MYC in several human metastatic melanoma lines via lentivirus-based shRNAs approximately to the levels detected in normal melanocytes. C-MYC depletion did not significantly affect levels of E2F1 protein reported to regulate expression of many S-phase specific genes, but resulted in the repression of several genes encoding enzymes rate-limiting for dNTP metabolism. These included thymidylate synthase (TS), inosine monophosphate dehydrogenase 2 (IMPDH2) and phosphoribosyl pyrophosphate synthetase 2 (PRPS2). C-MYC depletion also resulted in reduction in the amounts of deoxyribonucleoside triphosphates (dNTPs) and inhibition of proliferation. shRNA-mediated suppression of TS, IMPDH2 or PRPS2 resulted in the decrease of dNTP pools and retardation of the cell cycle progression of melanoma cells in a manner similar to that of C-MYC-depletion in those cells. Reciprocally, concurrent overexpression of cDNAs for TS, IMPDH2 and PRPS2 delayed proliferative arrest caused by inhibition of C-MYC in melanoma cells. Overexpression of C-MYC in normal melanocytes enhanced expression of the above enzymes and increased individual dNTP pools. Analysis of in vivo C-MYC interactions with TS, IMPDH2 and PRPS2 genes confirmed that they are direct C-MYC targets. Moreover, all three proteins express at higher levels in cells from several metastatic melanoma lines compared to normal melanocytes. Our data establish a novel functional link between C-MYC and dNTP metabolism and identify its role in proliferation of tumor cells.

MeSH Terms
Cell Proliferation/drug effects Gene Expression Regulation, Enzymologic/drug effects Gene Expression Regulation, Neoplastic/drug effects Humans IMP Dehydrogenase/genetics,metabolism,physiology Melanocytes/metabolism Melanoma/genetics,metabolism,pathology Nucleotides/biosynthesis Promoter Regions, Genetic Protein Binding Proto-Oncogene Proteins c-myc/antagonists & inhibitors,genetics,metabolism,physiology RNA, Small Interfering/pharmacology Ribose-Phosphate Pyrophosphokinase/genetics,metabolism,physiology Thymidylate Synthase/genetics,metabolism,physiology Transfection Tumor Cells, Cultured
Chemicals
Nucleotides Proto-Oncogene Proteins c-myc RNA, Small Interfering IMP Dehydrogenase IMPDH2 protein, human Thymidylate Synthase Ribose-Phosphate Pyrophosphokinase
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Mannava Sudha
Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Grachtchouk Vladimir
Wheeler Linda J
Im Michael
Zhuang Dazhong
Slavina Elena G
Mathews Christopher K
Shewach Donna S
Nikiforov Mikhail A
References (39)
39 references, click to expand
  1. Deoxyribonucleotide pool imbalance stimulates deletions in HeLa cell mitochondrial DNA.
    J Biol Chem. 2003 Nov 7;278(45):43893-6 PMID: 13679382
  2. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle.
    Oncogene. 2008 Mar 20;27(13):1905-15 PMID: 17906696
  3. Novel c-MYC target genes mediate differential effects on cell proliferation and migration.
    EMBO Rep. 2007 Jan;8(1):70-6 PMID: 17159920
  4. A functional screen for Myc-responsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolism.
    Mol Cell Biol. 2002 Aug;22(16):5793-800 PMID: 12138190
  5. Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer.
    Anticancer Res. 2004 Nov-Dec;24(6):3875-80 PMID: 15736425
  6. Structural aspects of interactions within the Myc/Max/Mad network.
    Curr Top Microbiol Immunol. 2006;302:123-43 PMID: 16620027
  7. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination.
    Cell Growth Differ. 1997 Oct;8(10):1039-48 PMID: 9342182
  8. Regulation of human ornithine decarboxylase expression by the c-Myc.Max protein complex.
    J Biol Chem. 1993 Dec 25;268(36):27277-85 PMID: 8262968
  9. Analysis of genomic targets reveals complex functions of MYC.
    Nat Rev Cancer. 2004 Jul;4(7):562-8 PMID: 15229481
  10. Transcriptional regulation by p53: one protein, many possibilities.
    Cell Death Differ. 2006 Jun;13(6):951-61 PMID: 16575405
  11. Linear models and empirical bayes methods for assessing differential expression in microarray experiments.
    Stat Appl Genet Mol Biol. 2004;3:Article3 PMID: 16646809
  12. IMP dehydrogenase: mechanism of action and inhibition.
    Curr Med Chem. 1999 Jul;6(7):545-60 PMID: 10390600
  13. Thymidylate synthase: structure, inhibition, and strained conformations during catalysis.
    Pharmacol Ther. 1997 Oct-Dec;76(1-3):29-43 PMID: 9535167
  14. MYC oncogenes and human neoplastic disease.
    Oncogene. 1999 May 13;18(19):3004-16 PMID: 10378696
  15. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27.
    EMBO J. 1999 Oct 1;18(19):5321-33 PMID: 10508165
  16. C-Myc-independent restoration of multiple phenotypes by two C-Myc target genes with overlapping functions.
    Cancer Res. 2005 Mar 15;65(6):2097-107 PMID: 15781619
  17. Quantitation of deoxyribonucleoside 5'-triphosphates by a sequential boronate and anion-exchange high-pressure liquid chromatographic procedure.
    Anal Biochem. 1992 Oct;206(1):178-82 PMID: 1456431
  18. Elevated levels of thymidylate synthase linked to neoplastic transformation of mammalian cells.
    Cell Cycle. 2004 Aug;3(8):1005-7 PMID: 15280655
  19. Deconstructing myc.
    Genes Dev. 2001 Aug 15;15(16):2023-30 PMID: 11511533
  20. An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants.
    Mol Cell Biol. 1995 May;15(5):2527-35 PMID: 7739536
  21. Identification of CDK4 as a target of c-MYC.
    Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2229-34 PMID: 10688915
  22. Effects of biological DNA precursor pool asymmetry upon accuracy of DNA replication in vitro.
    Mutat Res. 2002 Feb 20;499(2):197-211 PMID: 11827713
  23. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
    Int J Cancer. 2004 Dec 10;112(5):733-7 PMID: 15386371
  24. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets.
    Genome Biol. 2003;4(10):R69 PMID: 14519204
  25. Myc target transcriptomes.
    Curr Top Microbiol Immunol. 2006;302:145-67 PMID: 16620028
  26. Conditional transgenic models define how MYC initiates and maintains tumorigenesis.
    Semin Cancer Biol. 2006 Aug;16(4):313-7 PMID: 16935001
  27. Phosphoribosylpyrophosphate synthetase and the regulation of phosphoribosylpyrophosphate production in human cells.
    Prog Nucleic Acid Res Mol Biol. 2001;69:115-48 PMID: 11550793
  28. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species.
    Cancer Res. 2006 Jul 1;66(13):6598-605 PMID: 16818632
  29. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability.
    Mol Cell. 2002 May;9(5):1031-44 PMID: 12049739
  30. Direct activation of TERT transcription by c-MYC.
    Nat Genet. 1999 Feb;21(2):220-4 PMID: 9988278
  31. Binding of myc proteins to canonical and noncanonical DNA sequences.
    Mol Cell Biol. 1993 Sep;13(9):5216-24 PMID: 8395000
  32. Transcriptional regulation and transformation by Myc proteins.
    Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 PMID: 16064138
  33. Mechanisms of transcriptional repression by Myc.
    Curr Top Microbiol Immunol. 2006;302:51-62 PMID: 16620025
  34. The c-Myc target gene network.
    Semin Cancer Biol. 2006 Aug;16(4):253-64 PMID: 16904903
  35. The MYC oncogene as a cancer drug target.
    Curr Cancer Drug Targets. 2003 Jun;3(3):163-75 PMID: 12769686
  36. Myc requires distinct E2F activities to induce S phase and apoptosis.
    Mol Cell. 2001 Jul;8(1):105-13 PMID: 11511364
  37. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
    Cancer Res. 2005 Jul 15;65(14):6294-304 PMID: 16024631
  38. Transcriptional activation by the Myc oncoprotein.
    Curr Top Microbiol Immunol. 2006;302:33-50 PMID: 16620024
  39. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression.
    Oncogene. 2006 Oct 30;25(51):6817-30 PMID: 17072330
Article Info
Journal
Cell cycle (Georgetown, Tex.)
Abbr.
Cell Cycle
ISSN
1551-4005
Published
2008-08-00
Epub
2008-00-03
Pages
2392-400
Language
English
Region
United States
NLM ID
101137841
PMCID
PMC3744895
Subset
IM
Grants
NCI NIH HHS · R01 CA083081 · United States
NCI NIH HHS · P30 CA046592 · United States
NCI NIH HHS · 5 P30 CA46592 · United States
NCI NIH HHS · R01 CA076581 · United States
NCI NIH HHS · R01-CA120244-A1 · United States
NCI NIH HHS · R01 CA120244 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com